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A comprehensive history from the patient and/or care-
giver is needed. There should be special focus on the 
history of the current complaint, past psychiatric his-
tory, past and present substance abuse history, full 
medical history and sexual risk history and the patient’s 
adherence to previous treatment regimens. Of equal 
importance is identification of social support systems.
A mental status examination will need to be conduct-
ed. In the psychotic patient one needs to focus specifi-
cally on the behaviour and appearance of the patient. 
His or her speech and speed of thoughts should be 
assessed, and mood symptoms, affect, suicidality and 
neuro-vegetative symptoms evaluated. Perceptual dis-
turbances, thought form, thought content and finally 
insight and judgement also need to be assessed. 
A comprehensive and meticulous physical and neuro-
logical examination should be performed to exclude 
any organic causes for the presenting psychiatric 
symptoms. A useful hierarchical approach has been 
suggested by Ambrosino et al.2 One should first exam-
ine for signs of delirium and rule out HIV-associated 
cognitive disorders. Medical diagnoses should first be 
considered and only after that should a psychiatric 
diagnosis be entertained. The differential diagnosis 
needs to consider the course of the HIV infection, the 
presence of a pre-existing psychiatric illness, use of 
illicit substances and the presence of cognitive impair-
ment.3
A useful delineation may be to divide psychosis in the 
PLWHA into: (i) psychiatric disorders predating HIV 
infection; (ii) new-onset psychotic disorders; and (iii) 
disorders associated with medical conditions (delirium) 
or substance intoxication or withdrawal, and those 
that are likely to be complications of treatment (i.e. 
antiretrovirals or antituberculosis drugs).4
PSYCHOTIC DISORDERS PREDATING HIV INFECTION
Major psychiatric disorders presenting with psycho-
sis and predating HIV infection include schizophrenia, 
bipolar mood disorder and major depressive disorder 
with psychotic features. These disorders present with 
significant impairment of functioning and follow a 
chronic course.5 Substance abuse may predispose and/
or precipitate a substance-induced psychotic disorder. 
There are a multitude of substances that may cause 
psychotic symptoms or psychotic disorders, and a clear 
collateral history is vital.
NEW-ONSET PSYCHOTIC DISORDERS
New-onset psychosis in the HIV-infected patient is the 
development of psychotic symptoms (delusions, hallu-
cinations, disorganised behaviour, negative symptoms 
or altered form of thought), either acutely or sub-
acutely, in the absence of concurrent substance abuse, 
opportunistic infections, space-occupying lesions, cog-
nitive impairment or various medications. It is hypo- 
thesised that this is caused by subcortical neurodegen-
eration and the direct neurotropic effects of HIV on the 
central nervous system (CNS), or is a manifestation of 
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The pathophysiology of psychosis and other forms of severe mental illness in HIV infection is complex, and 
multifactorial causation is likely in most instances. Severe mental illness has been identified as a risk factor for 
the acquisition of HIV infection and occurs as both a manifestation of opportunistic infections and a result of 
the neurotropic effects of the virus.1 A full psychiatric assessment in people living with HIV/AIDS (PLWHA) pre-
senting with psychosis is important but may prove difficult in many parts of South Africa. This paper presents a 
variety of algorithms to simplify the assessment and management of an HIV-infected patient with psychosis. 
APPROACH TO PlWHA AND PSYCHOSIS (FIG. 1) PSYCHOTIC DISORDERS IN PlWHA (FIG. 1)
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HIV-associated encephalopathy in the absence of se-
vere HIV-associated dementia. Some suggest that it is 
due to an increase in intracellular free calcium.6 Rates 
of new-onset psychosis in HIV-positive patients have 
been reported to range from 0.5% to 15%.7  
Psychotic symptoms may also occur in the presence of 
major HIV-related mood disorders. In a Ugandan study 
in which HIV-negative patients with primary mania and 
patients with HIV-related secondary mania were com-
pared, the patients with secondary mania were more 
irritable, aggressive and disruptive and had a higher rate 
of psychotic symptoms than those with primary mania.8 
Finally, new-onset psychotic symptoms may also occur 
in the presence of HIV related-cognitive disorders.9 
PSYCHOSIS ASSOCIATED WITH mEDICAl CONDITIONS, 
SUBSTANCE INTOXICATION, SUBSTANCE WITHDRAWAl 
OR AS A COmPlICATION OF mEDICATION
Delirium
Delirium often has multifactorial causation and mani-
fests with an acute presentation of disturbance in 
consciousness, change in cognition and development 
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of perceptual disturbances, with a fluctuating course.10 
It may be due to the presence of CNS opportunistic 
infections, metabolic disorders, neuropsychiatric side-
effects of various drugs, or substance intoxication or 
withdrawal. Studies from before the era of highly ac-
tive antiretroviral therapy (HAART) reported a preva-
lence of delirium of 12 - 29% among individuals with 
AIDS.11 The diagnosis of delirium depends on accurate 
diagnosis of the underlying cause. A comprehensive 
physical examination, diagnostic work-up (biochemical 
and microbiological parameters, cerebrospinal fluid ex-
amination) and brain imaging (computed tomography) 
are needed to help make the diagnosis. Hospitalised 
patients with HIV should be assessed early and fre-
quently for delirium, and treatment for the underlying 
cause should be initiated as soon as possible.
Substance intoxication or withdrawal
Substance intoxication and withdrawal are reversible 
substance-specific syndromes and may present with a 
delirium-type picture. HIV-infected individuals have a 
high prevalence of substance abuse, with lifetime rates 
as high as 50%.12 HIV-positive drug abusers are report-
ed to have higher rates of both HIV-associated demen-
tia and HIV encephalopathy than HIV-infected people 
who do not abuse drugs.13 Drug abuse may increase 
the risk of developing delirium. Furthermore, it may 
not only affect disease progression but also be associ-
ated with reduced adherence to antiretroviral therapy 
(ART) and is therefore a very important co-morbidity to 
consider in the patient with ‘triple diagnosis’ disorders, 
i.e. psychiatric disorders, HIV infection and substance 
abuse disorders.14 
Psychosis as a complication of medical treatment
Some medications used to treat HIV or the medical com-
plications of HIV/AIDS may cause psychiatric disorders 
presenting with psychotic symptoms. Efavirenz has been 
associated with a wide range of neuropsychiatric side-
effects. Psychotic symptoms associated with the com-
mencement of efavirenz therapy are reported to occur 
early on and may necessitate its discontinuation.15 
Other medications commonly used in HIV medicine 
that can be associated with mental state changes and 
psychotic symptoms include corticosteroids; other an-
tiviral agents, e.g. ganciclovir; antifungal agents, e.g. 
amphotericin B; and some antibacterials, e.g. anti- 
tuberculosis drugs, dapsone and sulphadiazines.4,16
These ‘psychotoxic’ reactions, which may manifest as 
psychosis, mania or delirium, have been associated 
with the commencement of treatment with isoniazid, 
ethionamide, ethambutol and some of the fluoroqui-
nolones. A study in Peru found that severe psychiatric 
syndromes associated with isoniazid occurred in ap-
proximately 1% of patients with tuberculosis between 
1991 and 1999.17 A careful history is therefore neces-
sary to determine the temporal relationship between 
the development of psychotic symptoms and com-
mencement of the drug, as this has very important im-
plications in terms of management. 
When a patient presents with psychotic symptoms in 
the presence of HIV infection it is essential to exclude 
life-threatening medical causes of the psychotic symp-
toms. This may be extremely difficult in the agitated, 
Fig. 2. Psychotic disorders predating HIV infection.

























with psychosis, predating HIV
diagnosis
Treat underlying psychiatric
condition optimally – it may be
necessary to refer to a
psychiatrist for optimal control
Investigate home circumstances
and support
Refer to government ART
clinic for work-up and
commencement of ART
Reinforce adherence to
medication. Refer to specialist
centre for psychiatric follow-up
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disorganised or violent patient, and antipsychotic med-
ications may need to be instituted before a thorough 
work-up is completed. Antipsychotic medications are 
safe and effective in the presence of HIV disease, but 
treatment modifications may be necessary and con-
servative dosing strategies may need to be implement-
ed. Antipsychotic medication should always be used 
at the lowest possible dose for the shortest possible 
duration.
The choice of antipsychotic drugs depends largely on 
the patient, presenting symptoms, past response, po-
tential side-effect profile, possible drug interactions, 
cost, and pill burden of the chronically ill patient. 
Many patients with new-onset psychosis or psychosis 
associated with various medical conditions may only 
require short-term treatment with antipsychotic medi-
cation. However, some patients may require long-term 
maintenance treatment with antipsychotic agents, 
and here special attention must be paid to the follow-

























Treat psychotic symptoms with typical
agents, i.e haloperidol 0.5 mg - 2.5 mg p.o.
nocte and/or lorazepam 1 - 2 mg p.o. q 8 h.
Observe for side-effects
If extrapyramidal side-effects
occur, change to atypical agent,
i.e. risperidone 1 - 2 mg p.o.






Once stable, investigate social
support and identify treatment
supporter
Work up for ART and commence
ART in line with DoH guidelines,
paying attention to neuropsychiatric
side-effects of ART and drug-drug
interactions
Reinforce adherence to medication.
Refer to specialist centre for
psychiatric follow-up
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ing factors. The typical antipsychotics are commonly 
used in resource-constrained settings. Here low doses 
of haloperidol (0.5 - 2.5 mg) and chlorpromazine (25 
- 50 mg) have proven effective and safe. Vigilance is 
required with regard to extrapyramidal side-effects 
with haloperidol and anticholinergic side-effects with 
chlorpromazine. 
Among the atypical antipsychotics, risperidone (1 - 
4 mg/d) is commonly used, if available. This may be 
used in patients who present with or pose a risk of 
developing extra-pyramidal side-effects. The atypical 
antipsychotics are generally better tolerated than the 
typical antipsychotics, but they are associated with 
longer-term metabolic side-effects and the potential 
development of drug-drug interactions. Development 
of the metabolic syndrome, weight gain, abnormal li-
pid profiles and diabetes mellitus are well described 
with some of the atypical antipsychotics (olanzapine 
and clozapine). The lipodystrophy syndrome described 
in HIV-positive patients on ART predisposes these pa-
tients to the development of diabetes mellitus and 
coronary artery disease. The atypical antipsychotics 
with a propensity to develop metabolic syndrome and 
certain ART regimens (protease inhibitors (PIs) and the 
nucleoside reverse transcriptase inhibitors (NRTIs) in 
particular), taken together, may have serious long-term 
adverse effects.18,19 
Many psychotropic medications and ART (especially 
the PIs and NNRTIs) share the same cytochrome P450 
(CYP) iso-enzymes for metabolism, and competition 
between the two is prominent.18,19 Interactions result-
ing in a decreased plasma concentration-time curve 
Fig. 4. Psychosis associated with medical conditions or substance intoxication/withdrawal, or resulting from medication-
related side-effects.
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for olanzapine may be clinically important.20 For other 
important interactions, see the article in this issue on 
psychotropic prescribing.
It may be necessary to make use of benzodiazepines in 
the agitated, aggressive patient when antipsychotics 
alone do not provide sufficient containment. The use 
of benzodiazepines with few or no active metabolites 
is crucial. Lorazepam in small divided doses may be 
necessary, i.e. 1 - 2 mg orally every 8 hours. Caution 
is needed when using lorazepam in the patient with 
delirium, as one study found it to be ineffective and 
associated with significant adverse effects.21 However, 
this agent may be the only drug available in certain 
resource-limited settings, and benefit versus risk will 
need to be ascertained for each individual patient.
Psycho-education is imperative throughout all stages 
of treatment. Psychosocial interventions and regular 
follow-up with the multidisciplinary team (psychia-
trist, psychiatric nurse, social worker, occupational 
therapist and psychologist) are important. Adherence 
should consistently be reinforced and improved. Re-
ferral to an occupational therapist who uses various 
activity groups, support groups and food garden/nutri-
tion security groups to help improve adherence may be 
considered. Supportive therapy is vitally important as 
the patient recovers. Temporary placement in an ap-
propriate facility may be necessary for patients who 
are difficult to treat and those who require longer in-
patient care.
Ongoing viral replication in the brain is a risk factor for 
neuropsychiatric disorders, and in combination with de-
gree of immunodeficiency and other factors that lower 
the threshold for developing psychosis (family history, 
substance abuse) these constitute a stress-within-a-
stress diathesis model. It is often not realistic to start 
ART in a psychotic patient without antipsychotics as 
adherence is likely to be poor, but once the patient has 
reached a state of relative stability ART should be start-
ed as soon as possible to decrease the contribution of 
HIV replication in the brain. In patients with psychosis 
related to immunosuppression and brain dysfunction, 
treatment with antipsychotics and ART simultaneously 
may be necessary from the time of initial presentation. 
It is vitally important that the patient be monitored 
closely, either as an inpatient if difficult to contain, or 
very closely by caregivers to ensure intensive adher-
ence. Adherence counselling at all stages of recovery 
is imperative to ensure understanding of the need for 
ART and adherence to prevent possible resistance.
It is difficult to recommend a time frame with regard 
to duration of antipsychotic medication, as there is a 
relative paucity of literature. A possible option is to 
wean the patient slowly off antipsychotics after psy-
chotic symptoms have remitted for 6 months, then 
take a watch-and-wait approach. This must only be 
done if good follow-up is possible so that antipsychotic 
medication can be reintroduced the moment symptoms 
recur.
In order to simplify the management of psychosis in the 
HIV-positive patient, three algorithms are presented. Fig. 
2 describes the management of psychotic disorders pre-
dating HIV infection, Fig. 3 details the treatment and 
referral procedure for new-onset psychosis, and Fig. 4 
describes the process for the assessment, management 
and referral of psychosis associated with medical condi-
tions, substance intoxication/withdrawal and symptoms 
resulting from medication-related side-effects.
Commencement of ART may be initiated in accordance 
with the Department of Health guidelines.22 Depart-
ment of Health first-line regimens are used, but special 
attention needs to be paid to co-existing antituberculo-
sis treatment, liver toxicity, drug-drug interactions and 
possible neuropsychiatric side-effects of various ARTs. 
Ideally commencement of ART in the patient with psy-
chosis should be instituted in a multidisciplinary set-
ting. Adherence is an important concern in preparing 
patients for lifelong ART, but it is also crucial not to ex-
clude patients with serious mental illness from receiv-
ing ART because they may ‘possibly’ be non-adherent. 
Involvement of a treatment supporter is essential to 
assist with adherence, with the patient’s consent or as-
sent. Intensive pretreatment education and adherence 
counselling of the patient and treatment partner are 
vital in order to assess treatment appropriateness and 
commitment to long-term neuropsychiatric follow-up. 
It is imperative to exclude an underlying medical cause 
for psychotic symptoms in the HIV-infected patient, 
and a careful differential diagnosis needs to be estab-
lished based on the criteria set out above. Psychotic 
symptoms respond well to antipsychotic medication, 
but medication side-effects and drug-drug interac-
tions must be vigilantly watched out for. It is important 
to remember that patients with mental illness are at an 
increased risk of being infected with HIV and of trans-
mitting the virus. Prevention strategies, testing and 
referral of patients with mental illness and HIV/AIDS 
is vital. The algorithmic approach offered here serves 
to simplify and unite the assessment and treatment 
of psychosis in the HIV-positive patient at all levels of 
health care. 
CONClUSION
COmmENCEmENT AND CHOICE OF ARV DRUGS 
FOllOWING COmPREHENSIVE WORK-UP AND 
REmISSION OF PSYCHOTIC SYmPTOmS
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